CA2576886A1 - Proteines de liaison au complexe tie - Google Patents
Proteines de liaison au complexe tie Download PDFInfo
- Publication number
- CA2576886A1 CA2576886A1 CA002576886A CA2576886A CA2576886A1 CA 2576886 A1 CA2576886 A1 CA 2576886A1 CA 002576886 A CA002576886 A CA 002576886A CA 2576886 A CA2576886 A CA 2576886A CA 2576886 A1 CA2576886 A1 CA 2576886A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- antibody
- tiel
- variable domain
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/026116 WO2005019267A2 (fr) | 2003-08-12 | 2004-08-12 | Ligands se fixant au tie 1 |
US10/916,840 US7348001B2 (en) | 2003-08-12 | 2004-08-12 | Tie1-binding ligands |
USPCT/US2004/026116 | 2004-08-12 | ||
US10/916,840 | 2004-08-12 | ||
US11/049,536 | 2005-02-02 | ||
US11/049,536 US7871610B2 (en) | 2003-08-12 | 2005-02-02 | Antibodies to Tie1 ectodomain |
PCT/US2005/028413 WO2006020706A2 (fr) | 2004-08-12 | 2005-08-09 | Proteines de liaison au complexe tie |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2576886A1 true CA2576886A1 (fr) | 2006-02-23 |
Family
ID=35908119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002576886A Abandoned CA2576886A1 (fr) | 2004-08-12 | 2005-08-09 | Proteines de liaison au complexe tie |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1789451A4 (fr) |
JP (1) | JP2008532476A (fr) |
AU (1) | AU2005272848A1 (fr) |
CA (1) | CA2576886A1 (fr) |
WO (1) | WO2006020706A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
EP2322622A3 (fr) * | 2005-03-25 | 2012-03-07 | National Research Council of Canada | Procédé d'isolation de polypeptides solubles |
CA2606576A1 (fr) | 2005-05-20 | 2006-11-23 | Lonza Biologics Plc. | Expression de niveau eleve d'un anticorps recombinant d'une cellule hote de mammifere |
EP1981538B1 (fr) | 2005-12-30 | 2014-09-17 | Dyax Corporation | Proteines de liaison a la metalloproteinase |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
EA200802061A1 (ru) | 2006-03-28 | 2009-04-28 | Байоджен Айдек Эмэй Инк. | Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма |
EP2073826A4 (fr) * | 2006-10-17 | 2010-12-15 | Dyax Corp | Thérapie de combinaison séquentielle |
SI2129396T1 (sl) * | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
EP2036980A1 (fr) * | 2007-09-14 | 2009-03-18 | Gruber, Jens | Dérégulation de l'expression génétique à l'aide de particules semblables à un virus chargées d'acide nucléique |
SG10201605629VA (en) | 2008-01-03 | 2016-08-30 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
US8623592B2 (en) | 2008-08-15 | 2014-01-07 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
AU2009331528A1 (en) * | 2008-12-23 | 2011-08-11 | Astrazeneca Ab | Targeted binding agents directed to alpha5beta1 and uses thereof |
EA201201186A1 (ru) | 2010-03-11 | 2013-11-29 | Мерримак Фармасьютикалс, Инк. | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ |
CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
US9017670B2 (en) * | 2011-08-19 | 2015-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-Tie2 antibodies and uses thereof |
CA2907181C (fr) | 2013-03-15 | 2023-10-17 | Viktor Roschke | Complexes multispecifiques multivalents et monovalents et leurs utilisations |
EP3087394A2 (fr) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies |
EP3081575A1 (fr) * | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anticorps anti-plasmodium pour parasite |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2022199603A1 (fr) * | 2021-03-25 | 2022-09-29 | Nanjing GenScript Biotech Co., Ltd. | Protéines de fusion d'anticorps et leurs utilisations |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955291A (en) * | 1992-01-09 | 1999-09-21 | Alitalo; Kari | Antibodies recognizing tie receptor tyrosine kinase and uses thereof |
US6365154B1 (en) * | 1998-09-28 | 2002-04-02 | Smithkline Beecham Corporation | Tie2 agonist antibodies |
AU2004266242A1 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
-
2005
- 2005-08-09 EP EP05784935A patent/EP1789451A4/fr not_active Withdrawn
- 2005-08-09 CA CA002576886A patent/CA2576886A1/fr not_active Abandoned
- 2005-08-09 WO PCT/US2005/028413 patent/WO2006020706A2/fr active Application Filing
- 2005-08-09 AU AU2005272848A patent/AU2005272848A1/en not_active Abandoned
- 2005-08-09 JP JP2007525760A patent/JP2008532476A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006020706A2 (fr) | 2006-02-23 |
JP2008532476A (ja) | 2008-08-21 |
AU2005272848A1 (en) | 2006-02-23 |
EP1789451A4 (fr) | 2009-12-02 |
AU2005272848A2 (en) | 2006-02-23 |
WO2006020706A3 (fr) | 2006-10-12 |
EP1789451A2 (fr) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7485297B2 (en) | Method of inhibition of vascular development using an antibody | |
US7871610B2 (en) | Antibodies to Tie1 ectodomain | |
CA2576886A1 (fr) | Proteines de liaison au complexe tie | |
US20080254021A1 (en) | Tie1-binding ligands | |
JP6779944B2 (ja) | 血漿カリクレイン結合タンパク質 | |
JP5898649B2 (ja) | マトリックスメタロプロテイナーゼ結合タンパク質 | |
US20080075723A1 (en) | Endotheliase 2 ligands | |
EP3262075B1 (fr) | Nouvel anticorps se liant à la tfpi et composition le comprenant | |
US20100291001A1 (en) | Metalloproteinase-binding proteins | |
US20180193456A1 (en) | Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies | |
JP2007528720A5 (fr) | ||
KR20080068108A (ko) | 작용-차단성 항-ed-b-피브로넥틴 항체의 동정 및 특징화 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |